- Nucala is the first and only monthly biologic approved in China studied in a wide COPD population with blood eosinophil count (BEC) starting as low as 150 cells/µL
- Approval based on the positive MATINEE and METREX phase III trials
- MATINEE data…
Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD)
